Article Text

PDF
Bosentan therapy for patients with severe Raynaud’s phenomenon in systemic sclerosis
  1. M E Hettema,
  2. D Zhang,
  3. H Bootsma,
  4. C G M Kallenberg
  1. Department of Internal Medicine, Division of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, the Netherlands
  1. Dr M E Hettema, Division of Rheumatology and Clinical Immunology, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, the Netherlands; m.e.hettema{at}int.umcg.nl

Statistics from Altmetric.com

Raynaud’s phenomenon (RP) is present in more than 95% of patients with systemic sclerosis (SSc). Its frequency and severity in combination with the presence of digital ulcers affect the quality of life of patients.1 Although the aetiology of RP is multifactorial, endothelin-1 has been suggested to play a role in its pathogenesis.2 Bosentan, an endothelin-1 receptor antagonist, has been shown to be effective in preventing the occurrence of new digital ulcers when compared with placebo.3

Against this background, we hypothesized that bosentan can be a useful and effective strategy in SSc patients with RP. Therefore we assessed the effects of bosentan …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.